<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ipharmsciencia.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Internationale-Pharmaceutica-Sciencia-ISSUE VOLUME Volume 12 ISSUE Issue 1</title>
<link>http://ipharmsciencia.edwiserinternational.com/rss-feed.php</link>
<description>
Internationale-Pharmaceutica-Sciencia: VOLUME Volume 12 ISSUE Issue 1,  2021
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Internationale-Pharmaceutica-Sciencia-ISSUE VOLUME Volume 12 ISSUE Issue 1</title>
<link>http://ipharmsciencia.edwiserinternational.com/rss-feed.php</link>
<url>http://ipharmsciencia.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Is-the-New-Approach-in-Inflammatory-Bowel-Disease-Treat-to-Target</title>
		<pubDate>29-Mar-2021</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/UYhy2K.pdf</link>
		<author>Vinod-Kumar-P</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Inflammatory bowel disease is a chronic inflammatory disease of which the etiology is unknown. Ulcerative colitis and Crohn's disease are the two main entities of inflammatory bowel disease that are challenging clinicians. In addition to tumor necrosis factor blockers, this overview summarizes current and future new drugs, in the treatment of inflammatory bowel disease according to their goals. The infiltration of lymphocytes into the intestinal lining is a target for therapeutic purposes in inflammatory bowel disease. The vascular cell adhesion molecule-1 and the mucosal addressin cell adhesion molecule-1 are a family of integrins for the alpha4 that are specifically expressed in the alimentary canal on vascular endothelial cells. In Crohn's disease, the alpha4beta7 integrin, and its endothelial receptor, the mucosal addressin cell adhesion molecule-1, have proven to be a relevant factor in the development of chronic intestinal inflammation. New biological and chemical drugs are emerging, with additional molecules pending approval.]]>}</description>
		</item><item>
		<title>Vedolizumab-in-Ulcerative-Colitis-and-Crohns-Disease-A-Systematic-Review</title>
		<pubDate>15-Jun-2021</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/c0TAUC.pdf</link>
		<author>P-Vinod-Kumar</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Background: Vedolizumab is a fully humanized monoclonal IgG-1 antibody that selectively inhibits the interaction between 47 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). It prevents lymphocyte translocation from the blood into the inflamed gut tissue, resulting in a reduction in local inflammation. Ulcerative colitis (UC) and Crohns disease (CD) are inflammatory conditions of the bowel affecting approximately 1.4 million people in the US. The efficacy of the drug was studied.Methods: The outcome measures for Phase 3 and randomized clinical trials in ulcerative colitis and Crohns disease, was as per GEMINI 1, 2, and 3 for its efficacy.  Results: A total of 309 out of 499 reported vedolizumab AEs. In comparison with all other drugs, 3PRR signals were detected including joint-related symptoms like arthralgia, upper respiratory tract infections like nasopharyngitis and sinusitis, and upper respiratory tract symptoms like oropharyngeal pain. Among the vedolizumab-associated reports with serious outcomes, the drug was used for CD in 52.5% and UC in 27.4% compared with 86.1% and 13.9% for the anti-TNFs-associated reports. Although safety data from both these studies suggest VDZ is safe, larger studies with longer follow-up will be necessary to determine the potential risk for the development of PML.Conclusion: There is limited information on other potential confounders, such as co-morbidities, duration, and severity of disease, disease phenotype, surgical history, smoking, and concurrent IBD treatment. The benefit and risk profile of combining Vedolizumab with anti-TNF- agents in the treatment of IBD will need to be examined. Vedolizumab is revolutionary in the community of inflammatory bowel disease, especially with the potential advantage for VDZs selectivity to the gastrointestinal immune system. Vedolizumab provides an alternate class to biologic therapy with an encouraging response and safety profile.]]>}</description>
		</item><item>
		<title>Superiority-of-Angiotensin-II-Receptor-Blockers-over-Angiotensin-Converting-Enzyme-Inhibitors-in-Stroke-Prophylaxis</title>
		<pubDate>23-Jun-2021</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/pbjdRg.pdf</link>
		<author>Hussaini-Sand-Sayed-S</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Angiotensin II receptor blockers provide better protection against stroke than Angiotensin converting enzyme inhibitors among the elderly population suffering from systolic hypertension. This research paper examines a series of published studies examining the superiority of angiotensin receptor blockers in stroke prophylaxis.The study designs identified during the research include clinical studies and systematic reviews. An evidence table was made to analyze the researched data. A thorough analysis was performed of the angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, and their mechanism of action as well as their pathophysiological effects. The results of the clinical trials demonstrated that angiotensin II receptor blockers indeed reduce stroke incidence in hypertensive patients. Angiotensin converting enzyme inhibitors were found to have no effect on stroke incidence, while two studies showed that they increased the incidence of stroke in hypertensives compared to a conventional anti-hypertensive therapy.After a head-to-head comparison of the two-drug regimen, with substantial clinical and experimental evidence supporting the research hypothesis, it can be concluded that angiotensin II receptor blockers are indeed a superior choice in stroke prophylaxis in the elderly population suffering from isolated systolic hypertension.]]>}</description>
		</item><item>
		<title>A-review-of-Quinolones-Pharmacological-Activity</title>
		<pubDate>23-Jun-2021</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/avsDVw.pdf</link>
		<author>Vikrant-Verma-Kunal-Arora</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[In this review article various pharmacological activities of quinolones are dealt with. Quinolones have a broad and potent spectrum of activity and are also used as first and second-line drugs to treat different types of diseases. Recently, quinolones have been reported to display various biological activities. There is a huge research potential in this moiety and with the help of different substituents various derivatives with different biological activity can be obtained. The present review focuses on the structural modifications responsible for the different biological activities.]]>}</description>
		</item><item>
		<title>In-Silico-Studies-to-Identify-Potential-Natural-Antiviral-Agents-to-Treat-and-Control-SARS-CoV-2-COVID-19</title>
		<pubDate>23-Jun-2021</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/07vH3D.pdf</link>
		<author>Shanu-Sharma</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Background: Recently, a new and fatal strain of coronavirus named as SARS-CoV-2 (Disease: COVID-19) appeared in Wuhan, China in December of 2019 and was officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses based on phylogenetic analysis. Because of its highly contagious nature, there is an urgent need for suitable drug which can control the viral infection. The covid 19 main protease was found to be the best target for drug synthesis as it involved in viral replication.Objective: The present in silico study was undertaken with an aim to investigate the anti-viral and anti-SARS CoV-2 activities of the chemical components found in the varieties of medicinal plants which could potentially inhibit the Covid 19 Mpro by molecular docking.Method: The selected ligands and protein were obtained from Pubchem database and PDB database. Docking studies was conducted by the help of Autodock vina, and the result analysis was done using PyMOL 2.5 and Biovia Discovery studio 3.5.Result: The docking results showed that all the selected compounds showed low binding energies and high affinity indicating that they could be used in the drug preparation against Covid 19. The binding energies of curcumin, bisdemethoxycurcumin, demethoxycurcumin, tetrahydro curcumin, daidzein, genistein, hypericin, pseudohypericin, proanthocyanidin, Quecetin, nimbocinol was found to be -5.7, -6.5, -5.7, -7.1, -7.4, -7.3, -10.4, -10.4, -7.1, -7.2, -7.0 kcal/mol.Conclusion: From the present study, it was concluded that the compounds used have a potential to be used as inhibitor of Covid 19 Mpro.However, these compounds need to be further optimized, and evalaute pharmacologically, in vivo, in vitro so that it could be used to treat COVID-19 and serve as a lead in the future for development of more effective natural antivirals against COVID-19.]]>}</description>
		</item></channel>